Sanofi India Ltd
Company Profile
Business description
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.
Contact
Saki Vihar Road
Sanofi House, CTS Number 117-B
L&T Business Park
Powai
MumbaiMH400072
INDT: +91 2228032000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
1,285
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
stocks
Bapcor is paying for the sins of its past
stocks
Overvalued ASX share as market underestimates downside risks
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,390.10 | 16.40 | 0.17% |
CAC 40 | 8,258.86 | 52.79 | 0.64% |
DAX 40 | 24,330.03 | 71.23 | 0.29% |
Dow JONES (US) | 46,978.56 | 271.98 | 0.58% |
FTSE 100 | 9,426.99 | 23.42 | 0.25% |
HKSE | 26,027.55 | 168.72 | 0.65% |
NASDAQ | 22,964.30 | 26.24 | -0.11% |
Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
S&P 500 | 6,741.01 | 5.88 | 0.09% |
S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
SSE Composite Index | 3,916.33 | 52.44 | 1.36% |